Celltrion Unveils KRW 1.2 Trillion Investment to Expand Drug Substance Manufacturing in Songdo, Boosting Total Capacity to 570,000 Liters
Celltrion has unveiled an ambitious large-scale investment strategy exceeding KRW 1 trillion aimed at significantly expanding its global manufacturing footprint and reinforcing its competitive position in the rapidly growing biologics market. The initiative, which will be implemented in phases through 2030, reflects the company’s proactive response to surging global demand for biosimilars and innovative biologic therapies, while also laying the groundwork for long-term, sustainable growth.
At the heart of this strategy is a major expansion of the company’s manufacturing infrastructure at its headquarters in Songdo, along with enhancements to its U.S. production base and other domestic facilities. Rather than focusing solely on capacity expansion, Celltrion’s plan is designed to build a fully integrated and flexible manufacturing ecosystem capable of supporting both its current commercial portfolio and its future pipeline of next-generation therapies.
A key component of this initiative is the planned construction of two new production facilities—Plants 4 and 5—at the Songdo campus. With an investment of approximately KRW 1.2265 trillion, these facilities will add a combined 180,000 liters of drug substance (DS) production capacity. Once operational, they are expected to play a central role in supporting the company’s expanding biosimilar pipeline as well as its contract manufacturing organization (CMO) business, which continues to attract increasing global interest.
The new plants will incorporate state-of-the-art automation systems and smart factory technologies, enabling a high degree of operational efficiency and flexibility. This advanced infrastructure will allow Celltrion to handle a broad range of manufacturing needs, from small-batch, multi-product runs to large-scale production campaigns. Such versatility is particularly important as the company prepares to launch new biologic products while maintaining supply for its established therapies. The integration of smart manufacturing solutions is also expected to optimize resource utilization, reduce production timelines, and enhance overall quality control.
In parallel with its expansion in South Korea, Celltrion is strengthening its presence in the United States by scaling up its manufacturing facility in Branchburg, New Jersey. The company has increased the planned expansion capacity from 66,000 liters to 75,000 liters, bringing the total DS production capacity at the site to 141,000 liters. This move underscores the growing importance of localized manufacturing in the U.S., where demand for biologics continues to rise and where domestic production capabilities can help mitigate risks associated with global supply chains and trade uncertainties.
The Branchburg facility is expected to serve as a critical hub for supplying the U.S. market and supporting Celltrion’s growing CMO business. By establishing a stronger manufacturing base in the United States, the company aims to enhance its responsiveness to local demand while also improving profitability through reduced logistics costs and greater operational efficiency.
Upon completion of all planned expansions in both Korea and the United States, Celltrion’s global DS production capacity will increase from the current 316,000 liters to approximately 571,000 liters. This substantial increase will enable the company to achieve full internalization of DS production, a strategic milestone that is expected to deliver significant cost savings and greater control over the manufacturing process.
In addition to its focus on DS manufacturing, Celltrion is making considerable investments in drug product (DP) production capabilities. At the Songdo campus, a new DP-only production facility is currently under construction and has already surpassed 70% completion. The plant is expected to be finalized within the year, with commercial operations scheduled to begin the following year. Once operational, the facility will be capable of producing up to 6.5 million liquid vials annually.
When combined with the existing DP production line at Plant 2, which has a maximum capacity of 4 million vials per year, Celltrion will achieve a total DP production capacity of approximately 10.5 million vials annually at Songdo alone. This expanded capacity will play a crucial role in ensuring the timely and efficient delivery of finished biologic products to global markets.
Further strengthening its DP manufacturing capabilities, Celltrion has selected a site for a new facility in the Yesan Industrial Complex in Chungcheongnam-do. Design work for this plant is expected to commence within the year. In parallel, Celltrion Pharm plans to expand its pre-filled syringe (PFS) production capabilities, further enhancing the company’s ability to meet diverse product format requirements.
Once these initiatives are completed, Celltrion anticipates internalizing approximately 90% of its global DP production volume. This high level of internalization is expected to yield substantial cost efficiencies compared to reliance on external contract manufacturers, while also improving supply chain reliability and quality assurance.
Safety remains a top priority across all of Celltrion’s expansion projects. The company has emphasized that it is conducting comprehensive reviews of safety management systems for all ongoing construction activities and is committed to maintaining the highest safety standards throughout the development and operation of its new facilities.
Strategically, these investments align with Celltrion’s global “two-track” manufacturing approach. Under this model, domestic facilities in South Korea will focus on maximizing production efficiency and cost competitiveness, enabling the company to strengthen its position in global tenders and expand its presence in markets outside the United States. Meanwhile, its U.S.-based operations will function as a localized supply hub, ensuring faster delivery to the American market and reducing exposure to potential trade barriers such as tariffs.
This dual approach not only enhances operational resilience but also positions Celltrion to respond more effectively to evolving market dynamics and economic conditions. By combining large-scale domestic production with targeted international expansion, the company is building a robust and adaptable manufacturing network capable of supporting its long-term growth ambitions.
Looking ahead, Celltrion has indicated that it may consider additional capacity expansions depending on market conditions and the progress of its product pipeline. This forward-looking stance reflects the company’s confidence in the continued growth of the biologics sector and its determination to remain at the forefront of innovation and manufacturing excellence.
Overall, this масштабный investment marks a significant step in Celltrion’s journey toward becoming a leading global biopharmaceutical company. By strengthening its manufacturing infrastructure, enhancing operational efficiency, and expanding its CMO capabilities, the company is well-positioned to meet the rising global demand for high-quality biologic therapies while delivering sustained value to patients and stakeholders worldwide.
Source Link: https://www.celltrion.com/
